(Neo:VERS.NE),(OTC US:VRSSF),(Other OTC:VRSSF),(OTC US:VRSSD),(Other OTC:VRSSD),(Neo:VERS), VANCOUVER, British Columbia, Dec. 19, 2025 (GLOBE NEWSWIRE) — VERSES AI Inc. (CBOE: VERS) (OTCQB: VRSSF) (“VERSES” or the “Company“), a cognitive computing company pioneering next-generation agentic software systems, is pleased to announce that it has closed a non-brokered private placement offering (the “Offering“) of secured convertible debenture units (the […]

(NASDAQ:LAES), Geneva, Switzerland, Dec. 19, 2025 (GLOBE NEWSWIRE) — SEALSQ Corp (NASDAQ: LAES) (“SEALSQ” or “Company”), a company that focuses on developing and selling Semiconductors, PKI, and Post-Quantum technology hardware and software products, today announced its strategic plan for 2026-2030 to advance quantum computing emerging from the semiconductor world, leveraging silicon and CMOS-compatible manufacturing processes

(TSX:LABS),(OTC US:MEDIF),(Other OTC:MEDIF),(Boerse Frankfurt – Freiverkehr:MLZ), TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids, welcomes U.S. President Donald Trump's executive order to expedite the reclassification of cannabis under the U.S. Controlled Substances Act from

(TSX:PRN),(NASDAQ:PROF), TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) — Profound Medical Corp. (Nasdaq:PROF; TSX:PRN) (“Profound” or the “Company”) today announced the sale of 5,142,857 common shares at a purchase price of $7.00 per share in a registered direct offering and a planned subsequent private placement in Canada of up to 571,428 common shares at a purchase

(NasdaqGM:LOVE), STAMFORD, Conn., Dec. 19, 2025 (GLOBE NEWSWIRE) — The Lovesac Company (Nasdaq: LOVE) (“Lovesac” or the “Company”), the Designed for Life home and technology brand, has released its ESG & Impact Report for the 2025 fiscal year ended February 2, 2025. This report highlights the company's continued focus on environmental sustainability, social responsibility, and

(OTCQB:INNMF),(OTC US:INNMF),(AUST:ATX.AX), HIGHLIGHTS The preclinical research collaboration with specialist drug screening company Next & Bio has been extended The collaboration explores the effect of Amplia's FAK inhibitors in combination with experimental drugs called kRas inhibitors kRas inhibitors are being developed for the treatment of pancreatic cancer and other solid tumours Melbourne, Australia, Dec. 19, 2025

SEALSQ Unveils Strategic Plan for 2026-2030 to Develop Silicon-Based Quantum Computing Using CMOS-Compatible Semiconductor Technologies GlobeNewswire December 19, 2025 Geneva, Switzerland, Dec. 19, 2025 (GLOBE NEWSWIRE) — SEALSQ Corp (NASDAQ: LAES) (“SEALSQ” or “Company”), a company that focuses on developing and selling Semiconductors, PKI, and Post-Quantum technology hardware and software products, today announced its strategic

Historic U.S. Cannabis Rescheduling Unlocks Potential Growth Opportunities for MediPharm Labs, Backed by the Company's Suite of Licenses and Proven U.S. Clinical Trial Supply Experience GlobeNewswire December 19, 2025 TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”) a pharmaceutical company specialized

Profound Medical Corp. Announces Pricing of up to $40 Million Financing Comprised of a $36 Million Registered Direct Offering and a Subsequent $4 Million Private Placement Financing included participation by healthcare-dedicated investors alongside existing shareholders GlobeNewswire December 19, 2025 TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) — Profound Medical Corp. (Nasdaq:PROF; TSX:PRN) (“Profound” or the “Company”)

The Lovesac Company Publishes 2025 ESG Report GlobeNewswire December 19, 2025 STAMFORD, Conn., Dec. 19, 2025 (GLOBE NEWSWIRE) — The Lovesac Company (Nasdaq: LOVE) (“Lovesac” or the “Company”), the Designed for Life home and technology brand, has released its ESG & Impact Report for the 2025 fiscal year ended February 2, 2025. This report highlights